Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15527494 | 0.87 | OPRK1 (0.50) | OPRK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10668140 | 0.85 | OPRK1 (0.49) | OPRK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL31284004 | 0.84 | CHEK2 (0.56) | OPRK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1887152 | 0.84 | CHEK2 (0.56) | OPRK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2782609 | 0.84 | OPRK1 (0.48) | OPRK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL20472328 | 0.84 | OPRK1 (0.48) | OPRK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL20472389 | 0.84 | OPRK1 (0.48) | OPRK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL18398582 | 0.84 | OPRK1 (0.48) | OPRK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL15527865 | 0.84 | OPRK1 (0.48) | OPRK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL11070776 | 0.83 | NPC1 (0.47) | MEN1KMT2ANPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724441-A1 | ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF | Revir Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4713313-A2 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | Springworks Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4605089-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | Mekanistic Therapeutics LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4577537-A1 | SUBSTITUTED BICYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| CN-120091998-A | Substituted bicyclic rings as HSET inhibitors | 默克专利股份公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025067457-A1 | HETEROCYCLIC FUSED RING COMPOUND, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-03-06 | — | — | US | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240417398-A1 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. | 2024-12-19 | — | — | US | disclosed |
| WO-2024251211-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR MODULATING SPLICING OF MSH3 | REVIR THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20160009712-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| WO-2014210042-A2 | METHOD FOR THE PREPARATION OF (1,2,4)-TRIAZOLO(4,3-A)PYRIDINES | AMGEN INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210042-A2 | METHOD FOR THE PREPARATION OF (1,2,4)-TRIAZOLO(4,3-A)PYRIDINES | AMGEN INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| US-8648200-B2 | Imidazole derivatives useful for the treatment of arthritis | ELI LILLY AND COMPANY (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120302608-A1 | Novel Imidazole Derivatives Useful for the Treatment of Arthritis | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012161965-A1 | NOVEL IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF ARTHRITIS | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| US-7030120-B2 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302608-A1 | Novel Imidazole Derivatives Useful for the Treatment of Arthritis | F12, IL1RN, ARG1 | OPRK1 48/4885MEN1 3664/4885KMT2A 3180/4885 |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | APOB, NCEH1, LIPC | OPRK1 870/4885MEN1 4072/4885KMT2A 2580/4885 |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | OPRK1 607/4885MEN1 3964/4885KMT2A 1408/4885 |
| US-20160009712-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM5A, KDM1A, KDM1B | OPRK1 3384/4885MEN1 2686/4885KMT2A 24/4885 |
| US-20240417398-A1 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | YAP1, TEAD2, TEAD1 | OPRK1 1325/4885MEN1 3370/4885KMT2A 2332/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | OPRK1 3281/4885MEN1 2696/4885KMT2A 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.